Sandoz Group AG (Sandoz Group AG) Accounts Receivable : $2,615 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Sandoz Group AG's accounts receivables for the quarter that ended in Dec. 2023 was $2,615 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Sandoz Group AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 23.91.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Sandoz Group AG's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-14.80.

Sandoz Group AG Accounts Receivable Historical Data

The historical data trend for Sandoz Group AG's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Accounts Receivable Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Accounts Receivable

2,207.00

2,615.00

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Accounts Receivable	2,207.00	2,615.00

Sandoz Group AG Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Sandoz Group AG Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Sandoz Group AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2615	/	9979	*	91
=	23.91

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Sandoz Group AG's accounts receivable are only considered to be worth 75% of book value:

Sandoz Group AG's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1109	+	0.75 * 2615	+	0.5 * 2700	-	10776
-	0	-	9)	/	429.929
=	-14.80

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Sandoz Group AG Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024